Pharmacology of Antibiotics
Learning Objectives
By the end of this page, you should be able to:
- Classify antibiotics by mechanism of action and explain why each mechanism achieves selective toxicity against bacteria.
- Distinguish time-dependent, concentration-dependent, and AUC/MIC-dependent killing and explain how each shapes dosing strategy.
- Describe the four major resistance mechanisms and give an example organism for each.
- Explain the principles of antimicrobial stewardship, including de-escalation and IV-to-oral switch criteria.
- Identify clinically important antibiotic drug interactions and the counseling points that go with them.
Quick Answer
Antibiotics work by exploiting structural and biochemical differences between bacterial and human cells — targeting cell wall synthesis, protein synthesis (70S vs. 80S ribosomes), DNA/RNA synthesis, cell membranes, or folate synthesis in ways that spare human cells. This selective toxicity is why antibiotics can be given systemically without poisoning the patient. Since penicillin's discovery in 1928, antibiotics have transformed medicine, but resistance — through enzymatic degradation, target modification, efflux pumps, and reduced permeability — is eroding that advantage faster than new drugs are being developed. For pharmacy students, antibiotic pharmacology means understanding not just what works, but why (mechanism), against what (spectrum), how to dose and monitor (PK/PD), and when not to prescribe (stewardship).
Antibiotics are antimicrobial agents that kill bacteria (bactericidal) or inhibit their growth (bacteriostatic), allowing the host immune system to clear the infection. The CDC estimates that >2.8 million antibiotic-resistant infections occur in the US annually, causing >35,000 deaths.
Mechanisms of Action
Bacteria differ structurally from human cells in several ways that antibiotics exploit:
1. Cell Wall Synthesis Inhibition
Bacteria have a rigid peptidoglycan cell wall that human cells lack. Disrupting its synthesis causes osmotic lysis.
- Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams): Bind to Penicillin-Binding Proteins (PBPs) — enzymes that cross-link peptidoglycan strands. Bactericidal.
- Glycopeptides (vancomycin, teicoplanin): Bind to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation. Active against Gram-positive bacteria only (too large to penetrate Gram-negative outer membrane).
2. Protein Synthesis Inhibition
Bacterial ribosomes are 70S (30S + 50S subunits); human ribosomes are 80S — a difference antibiotics selectively target.
| Drug Class | Ribosome Target | Bactericidal/Static | Key Example |
|---|---|---|---|
| Aminoglycosides | 30S subunit — irreversible | Bactericidal | Gentamicin, tobramycin, amikacin |
| Tetracyclines | 30S subunit — reversible | Bacteriostatic | Doxycycline, minocycline |
| Macrolides | 50S subunit | Bacteriostatic | Azithromycin, clarithromycin, erythromycin |
| Clindamycin | 50S subunit | Bacteriostatic | Clindamycin |
| Chloramphenicol | 50S subunit (peptidyl transferase) | Bacteriostatic | Chloramphenicol |
| Oxazolidinones | 50S + 30S (translation initiation) | Bacteriostatic | Linezolid |
3. DNA/RNA Synthesis Inhibition
- Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin): Inhibit DNA gyrase (topoisomerase II) in Gram-negatives and topoisomerase IV in Gram-positives → prevent DNA unwinding/religation → double-strand breaks → bactericidal.
- Rifamycins (rifampin): Bind bacterial RNA polymerase beta subunit → block transcription. Essential anti-TB agent; always combined (monotherapy causes rapid resistance).
- Metronidazole: Prodrug; reduced by anaerobic bacteria to toxic nitroso-radical intermediates that damage DNA. Bactericidal for anaerobes and protozoans.
4. Cell Membrane Disruption
- Polymyxins (colistin, polymyxin B): Bind lipopolysaccharide (LPS) of Gram-negative outer membrane → detergent-like disruption → leakage of cell contents. Bactericidal. Nephrotoxic and neurotoxic; reserved for multidrug-resistant (MDR) Gram-negatives.
- Daptomycin: Inserts into Gram-positive cytoplasmic membrane in a calcium-dependent manner → depolarization → bactericidal. Active against MRSA and VRE.
5. Folate Synthesis Inhibition
- Sulfonamides + Trimethoprim (TMP-SMX = Bactrim): Sequentially block folate synthesis (sulfonamides inhibit dihydropteroate synthase; TMP inhibits dihydrofolate reductase). Bacteriostatic. Human cells cannot synthesize folate → selective toxicity.
Classification and Spectrum of Activity
Beta-Lactams
The most widely used antibiotic class. All contain a beta-lactam ring; beta-lactamase enzymes (produced by resistant bacteria) can break this ring.
| Subclass | Key Drugs | Typical Spectrum |
|---|---|---|
| Natural penicillins | Penicillin G (IV), Penicillin V (oral) | Gram-positive streptococci, syphilis, oral anaerobes |
| Aminopenicillins | Ampicillin, amoxicillin | Gram-positives + some Gram-negatives (H. influenzae, E. coli) |
| Anti-staph penicillins | Nafcillin, oxacillin, dicloxacillin | MSSA only; penicillinase-resistant |
| Antipseudomonal penicillins | Piperacillin-tazobactam (Zosyn) | Broad spectrum including Pseudomonas |
| 1st-gen cephalosporins | Cefazolin (IV), cephalexin (oral) | MSSA; surgical prophylaxis standard |
| 3rd-gen cephalosporins | Ceftriaxone, ceftazidime | Gram-negative coverage, CNS penetration |
| 4th-gen cephalosporins | Cefepime | Broad Gram-negative including Pseudomonas |
| 5th-gen cephalosporins | Ceftaroline | MRSA activity + Gram-negative coverage |
| Carbapenems | Meropenem, imipenem, ertapenem | Broadest beta-lactam spectrum; ESBL-producing organisms |
| Monobactams | Aztreonam | Gram-negatives only; safe in penicillin allergy |
Glycopeptides — Vancomycin
- Use: MRSA, C. difficile (oral vancomycin), enterococcal infections
- Monitoring: AUC/MIC-based (target AUC 400–600 mg·h/L)
- Key ADR: Nephrotoxicity (especially with aminoglycosides); "Red Man Syndrome" (histamine-mediated — slow the infusion, not a true allergy)
- Resistance: VRE uses D-Ala-D-Lac instead of D-Ala-D-Ala → vancomycin cannot bind
Fluoroquinolones
- Ciprofloxacin: Best Gram-negative coverage including Pseudomonas; UTI, GI infections
- Levofloxacin: "Respiratory fluoroquinolone" — community-acquired pneumonia
- Moxifloxacin: Best Gram-positive and anaerobic coverage; no renal adjustment needed; NOT for UTI
- Black Box Warnings: Tendinopathy/tendon rupture, peripheral neuropathy, CNS effects, QT prolongation, worsening myasthenia gravis
Pharmacokinetic/Pharmacodynamic (PK/PD) Principles
| PD Parameter | Drug Classes | Optimization Strategy |
|---|---|---|
| Time-dependent killing (T>MIC) | Beta-lactams, carbapenems, vancomycin | Maximize time above MIC — extended infusions or more frequent dosing |
| Concentration-dependent killing (Cmax/MIC) | Aminoglycosides, fluoroquinolones | Maximize peak concentration — once-daily high-dose aminoglycosides |
| AUC/MIC-dependent | Glycopeptides, fluoroquinolones | Optimize total drug exposure over 24 hours |
Antibiotic Resistance Mechanisms
| Mechanism | How It Works | Example |
|---|---|---|
| Enzymatic degradation | Beta-lactamases hydrolyze beta-lactam ring | ESBL-producing E. coli, MRSA beta-lactamase |
| Target modification | Alter the antibiotic binding site | MRSA (PBP2a with low penicillin affinity) |
| Efflux pumps | Actively pump antibiotic out of cell | Tetracycline resistance; Pseudomonas MDR |
| Reduced permeability | Downregulate porin channels | Carbapenem resistance in Gram-negatives |
ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. — the most problematic MDR bacteria.
Antimicrobial Stewardship (US Context)
The CDC Core Elements of Hospital Antibiotic Stewardship:
- Leadership commitment: Dedicated resources for stewardship programs
- Accountability: Physician/pharmacist champion
- Drug expertise: Pharmacist with infectious disease training
- Action: Prospective audit + feedback; formulary restriction; de-escalation
- Tracking: Monitor antibiotic use (days of therapy/1000 patient-days)
- Reporting: Share results with prescribers
- Education: Provider and patient education
De-escalation: Start broad empirically, then narrow spectrum once culture sensitivities return — reduces resistance pressure and adverse effects.
IV-to-oral switch: Patient afebrile + hemodynamically stable + tolerating oral + adequate oral bioavailability → switch reduces IV catheter risk and shortens hospital stay.
Key Drug Interactions and Counseling Points
| Antibiotic | Important Interaction | Counseling Point |
|---|---|---|
| Ciprofloxacin | Raises warfarin INR; chelated by antacids/Ca²⁺/Fe²⁺ | Take 2h before or 6h after antacids |
| Azithromycin | QT prolongation; check other QT-prolonging drugs | Report palpitations, dizziness |
| Doxycycline | Chelated by dairy, antacids, iron | Take on empty stomach; avoid sun (photosensitivity) |
| TMP-SMX | Raises serum creatinine (blocks tubular secretion, not true GFR drop); hyperkalemia with ACEi/ARBs | Monitor K⁺ in patients on ACEi |
| Metronidazole | Disulfiram-like reaction with alcohol | No alcohol during and 48h after treatment |
| Linezolid | Serotonin syndrome with SSRIs/SNRIs; MAO-inhibiting properties | Avoid serotonergic drugs |
Penicillin allergy clarification: ~90% of self-reported penicillin allergy patients can safely take penicillin after formal allergy testing. Cross-reactivity between penicillins and cephalosporins is under 2% with modern agents.
Key Terms
| Term | Definition |
|---|---|
| Bactericidal | Kills bacteria directly |
| Bacteriostatic | Inhibits bacterial growth, relying on host immunity to clear infection |
| Beta-lactamase | A bacterial enzyme that hydrolyzes the beta-lactam ring, conferring resistance |
| Time-dependent killing | Efficacy correlates with time the drug concentration stays above the MIC |
| Concentration-dependent killing | Efficacy correlates with peak concentration relative to the MIC |
| MIC | Minimum inhibitory concentration — lowest antibiotic concentration that prevents visible bacterial growth |
| De-escalation | Narrowing antibiotic spectrum once culture sensitivities are known |
| ESKAPE pathogens | The group of multidrug-resistant organisms of greatest clinical concern |
Common Mistakes
Misconception 1: "A penicillin allergy label means the patient can never receive any beta-lactam." Why it's wrong: about 90% of patients with a self-reported penicillin allergy can safely tolerate penicillin after formal testing, and cross-reactivity with modern cephalosporins is under 2%. Correct: verify and, where appropriate, formally test reported allergies rather than automatically excluding an entire drug class, since unnecessary avoidance drives use of broader-spectrum alternatives and worsens resistance.
Misconception 2: "Bactericidal drugs are always better than bacteriostatic drugs." Why it's wrong: bacteriostatic drugs work perfectly well in patients with a competent immune system, and the "bactericidal is always superior" rule breaks down in serious infections requiring bactericidal action (e.g., endocarditis, meningitis, neutropenic sepsis) versus routine infections where either class is adequate. Correct: choose bactericidal vs. bacteriostatic based on infection severity and host immune status, not as a universal ranking.
Misconception 3: "Once-daily aminoglycoside dosing must be less effective because it's less frequent." Why it's wrong: aminoglycosides exhibit concentration-dependent killing, so a single large dose that maximizes peak concentration is actually more effective (and often less nephrotoxic) than smaller, more frequent doses. Correct: match the dosing strategy to the drug's PK/PD killing pattern — concentration-dependent drugs benefit from high peaks, while time-dependent drugs (beta-lactams) benefit from prolonged time above MIC via more frequent or extended infusions.
Comparison and Connections
| Concept A | Concept B | Key Difference |
|---|---|---|
| Bactericidal | Bacteriostatic | Bactericidal kills bacteria outright; bacteriostatic halts growth, relying on host immunity to finish clearance |
| Beta-lactams | Glycopeptides | Both inhibit cell wall synthesis, but beta-lactams bind PBPs directly while glycopeptides bind peptidoglycan precursors; glycopeptides only cover Gram-positives |
| Time-dependent killing | Concentration-dependent killing | Time-dependent drugs (beta-lactams) need prolonged exposure above MIC; concentration-dependent drugs (aminoglycosides) need a high peak relative to MIC |
| Empirical therapy | De-escalated therapy | Empirical therapy is broad-spectrum, started before culture results; de-escalated therapy is narrowed once sensitivities are known |
Practice Questions
Recall
- Name the five major mechanisms of antibiotic action. Answer guidance: cell wall synthesis inhibition, protein synthesis inhibition, DNA/RNA synthesis inhibition, cell membrane disruption, folate synthesis inhibition.
- What structural difference between bacterial and human ribosomes allows selective antibiotic targeting? Answer guidance: bacterial ribosomes are 70S (30S + 50S subunits) while human ribosomes are 80S, allowing drugs to target the bacterial subunit selectively.
Understanding
- Explain why vancomycin is active only against Gram-positive organisms. Answer guidance: vancomycin is too large a molecule to penetrate the outer membrane of Gram-negative bacteria, so it cannot reach the peptidoglycan precursors it needs to bind.
- Why does concentration-dependent killing favor once-daily, high-dose aminoglycoside regimens? Answer guidance: aminoglycoside efficacy correlates with peak concentration relative to MIC, so a single larger dose maximizes the peak-to-MIC ratio, and this dosing strategy has also been shown to reduce nephrotoxicity compared with more frequent smaller doses.
Application
- A patient started on empirical broad-spectrum antibiotics for pneumonia has culture results return showing a susceptible, narrow-spectrum-treatable organism. What stewardship action should follow, and why? Answer guidance: de-escalate to a narrower-spectrum agent matched to the culture sensitivities, reducing resistance pressure, cost, and adverse effect risk while maintaining efficacy.
- A patient on ciprofloxacin reports taking their antacid at the same time each day as their antibiotic dose and says the infection doesn't seem to be improving. What is the likely explanation and counseling fix? Answer guidance: divalent/trivalent cations in the antacid chelate ciprofloxacin, reducing its absorption; the patient should be counseled to separate dosing (antibiotic 2 hours before or 6 hours after the antacid).
Analysis
- Compare how enzymatic degradation and efflux pump resistance mechanisms would each affect the choice of a replacement antibiotic. Answer guidance: enzymatic degradation (e.g., beta-lactamases) can sometimes be overcome by adding a beta-lactamase inhibitor (e.g., tazobactam) or switching to a beta-lactamase-stable agent; efflux pump resistance actively removes the drug from the cell regardless of the drug's stability, so it often requires switching to an entirely different drug class not recognized by that pump.
- A hospital antimicrobial stewardship program wants to reduce vancomycin-resistant enterococcus (VRE) rates. Using resistance mechanism knowledge, explain why VRE is resistant and propose one stewardship-aligned strategy. Answer guidance: VRE alters its peptidoglycan precursor terminus from D-Ala-D-Ala to D-Ala-D-Lac, preventing vancomycin from binding; since resistance often develops under selective pressure from vancomycin overuse, a stewardship strategy would include restricting empirical vancomycin use to cases with a clear indication and de-escalating promptly once cultures allow a narrower choice.
FAQ
Q1: Why do doctors sometimes prescribe a bacteriostatic drug instead of a bactericidal one? Because for most infections in patients with normal immune function, halting bacterial growth is enough to let the immune system clear the infection, and bacteriostatic drugs can have a better side-effect or interaction profile for the specific situation.
Q2: Why is antibiotic resistance considered such an urgent problem? Because resistant infections are harder and more expensive to treat, often require more toxic last-resort drugs, and the pipeline of genuinely new antibiotic classes has slowed dramatically compared with the mid-20th century, so resistance can outpace new drug development.
Q3: What is the practical difference between empirical and definitive antibiotic therapy? Empirical therapy is a broad-spectrum best guess started before culture results are available, chosen to cover the most likely pathogens; definitive therapy is the narrower, targeted regimen chosen once culture and sensitivity results identify the exact organism and its susceptibilities.
Q4: Why does the FDA require a boxed warning on fluoroquinolones? Post-marketing surveillance identified risks of tendinopathy/tendon rupture, peripheral neuropathy, CNS effects, and worsening of myasthenia gravis that were serious enough to warrant the strongest label warning, reserving fluoroquinolones for infections where alternatives aren't suitable.
Q5: How does IV-to-oral switching benefit patients without compromising treatment? When a patient is afebrile, hemodynamically stable, tolerating oral intake, and the antibiotic has good oral bioavailability, switching achieves equivalent blood levels while reducing IV catheter-related infection risk, cost, and length of hospital stay.
Quick Revision
- Antibiotics achieve selective toxicity by targeting bacterial structures/processes absent or different in human cells (cell wall, 70S ribosomes, folate synthesis).
- Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams) inhibit PBPs; glycopeptides (vancomycin) block peptidoglycan precursor cross-linking and only cover Gram-positives.
- Aminoglycosides and fluoroquinolones show concentration-dependent killing (maximize peak); beta-lactams and vancomycin show time-dependent/AUC-dependent killing (maximize time above MIC or total exposure).
- Resistance arises via enzymatic degradation (beta-lactamases), target modification (MRSA's PBP2a), efflux pumps, and reduced membrane permeability.
- ESKAPE pathogens represent the most problematic multidrug-resistant organisms clinically.
- Antimicrobial stewardship relies on de-escalation, IV-to-oral switching, and tracking antibiotic use to slow resistance development.
- ~90% of self-reported penicillin allergies are not confirmed on formal testing; cephalosporin cross-reactivity is under 2%.
- Key interactions to counsel on: fluoroquinolones/tetracyclines chelated by divalent cations, metronidazole's disulfiram-like alcohol reaction, linezolid's serotonin syndrome risk with SSRIs.
Related Topics
Prerequisites
Related Topics
Next Topics